



Supplementary Figure S3. Forest plot of sensitivity analysis for extending analysis to underrepresented groups using a propensity-score—weighted analysis for ARB vs ACEi use for primary composite outcome. Primary composite outcome is cardiovascular related death, myocardial infarction, stroke, or hospitalisation for heart failure. On-treatment approach censored at treatment discontinuation (i.e., treatment gap of >90 days), switch treatment or start of dual use +60 days. Multiple imputation of missing baseline blood pressure and creatinine using chained equations. Eligible period <2011 is analysis restricted to start of trial-eligible periods prior to 2011. P value is test for heterogeneity using an term interaction between treatment and ethnicity in the Cox proportional hazards model.